New York, NY, June 21, 2016 --(PR.com
)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Jonathan Berman, Partner, Jones Day will speak at the Knowledge Group’s webcast entitled: “Product-Hopping in the Pharmaceutical Industry: Antitrust Issues to Watch For in 2016” This event is scheduled for July 26, 2016 from 12:00pm – 1:00pm (ET).
For further details, please visit:
About Jonathan Berman
Jonathan Berman has over 20 years of litigation experience, focusing on antitrust cases, class actions, and other complex litigation matters. He focuses on the interplay between civil litigation and the laws administered by the Food and Drug Administration. Jonathan also has advised clients, on dozens of matters, regarding FDA law and practice.
Jonathan's antitrust docket has included cases involving allegations of product-hopping, pay-for-delay, and price-fixing, government challenges to mergers, exclusive contracts, and a variety of rule-of-reason and monopolization theories. He frequently litigates on behalf of clients in the health care sector. Jonathan has represented, in major litigation, pharmaceutical companies, a drug wholesaler, an insurer, and hospitals.
About Jones Day
Jones Day is a global law firm with 43 offices in major centers of business and finance throughout the world. Its unique governance system fosters an unparalleled level of integration and contributes to its perennial ranking as among the best in the world in client service. Jones Day provides significant legal representation for almost half of the Fortune 500, Fortune Global 500, and FT Global 500.
One of the antitrust issues expected to surge the drug industry this 2016 is the legal developments concerning the practice of product-hopping or “forced switching.” The U.S. government is getting critical in this tactic which thwarts generic competition. Recent lawsuits prove the government’s increased scrutiny of product-hopping. The appellate decision in a related case upheld the injunction which requires the continued availability of an older drug until generic entry, after the introduction of the drug’s new version. This is to facilitate generic competition.
It is of paramount importance that in introducing a new drug formulation, branded drug firms must still consider the risk of a product-hopping lawsuit, which will eventually attract certain enforcement agencies.
In this two-hour live Webcast, a panel of distinguished professionals and thought leaders will help drug companies understand the fundamental aspects of Product-Hopping in the Pharmaceutical Industry. They will provide an in-depth discussion of this significant topic. Speakers will also offer best practices in developing and implementing an effective strategy for the introduction of a new drug formulation.
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/